Overview / Abstract: |
Recent years have seen an increase in the number of therapeutic monoclonal antibodies (mAbs) that are available to treat a variety of conditions caused by immune-mediated chronic inflammation such as psoriasis. Health care professionals are often presented with complex and conflicting information surrounding concepts of mAb production and immunogenicity; therefore, there is a significant need for education in this area, especially as distinguishing the relative clinical efficacy and safety profiles of one mAb relative to another can be difficult and complex due to different clinical designs and a lack of head-to-head comparator studies. In this CME Outfitters interactive infographic expert faculty evaluates the development of mAbs and anti drug antibodies (ADAs) by analyzing the history of and present-day inconsistencies in the nomenclature and their effects on therapeutic response. |
Expiration |
Nov 19, 2020 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.0 AMA PRA Category 1 Credit(s)TM/contact hours/CEUs |
Accreditation |
ACCME, AANP, AAPA, MACRA, ABIM |
Presenters / Authors / Faculty |
Alan Menter, MD |
Sponsors / Supporters / Grant Providers |
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com |
Keywords / Search Terms |
CME Outfitters, LLC Psoriasis, dermatology, derm Free CE CME |